Results 21 to 30 of about 37,133 (255)

Is follow-up BRAF(V600E) mutation analysis helpful in the differential diagnosis of thyroid nodules with negative results on initial analysis? [PDF]

PLoS ONE, 2013
BACKGROUND: We evaluated the usefulness of follow-up BRAF(V600E) mutation analysis using ultrasonography-guided fine-needle aspiration (US-FNA) in diagnosis of thyroid nodules showing negative BRAFV600E mutation on prior analysis.
Jung Hyun Yoon, Eun-Kyung Kim, Hee Jung Moon, Jin Young Kwak   +3 more
doaj   +1 more source

Recombinant methioninase (rMETase) is an effective therapeutic for BRAF-V600E-negative as well as -positive melanoma in patient-derived orthotopic xenograft (PDOX) mouse models. [PDF]

, 2017
Melanoma is a recalcitrant disease. Melanoma patients with the BRAF-V600E mutation have been treated with the drug vemurafenib (VEM) which targets this mutation.
Chmielowski, Bartosz, Dry, Sarah M, Eilber, Fritz C, Han, Qinghong, Hoffman, Robert M, Igarashi, Kentaro, Kawaguchi, Kei, Kiyuna, Tasuku, Li, Shukuan, Li, Yunfeng, Miyake, Kentaro, Miyake, Masuyo, Murakami, Takashi, Nelson, Scott D, Russell, Tara A, Tan, Yuying, Unno, Michiaki   +16 more
core   +1 more source

CRAF R391W is a melanoma driver oncogene. [PDF]

, 2016
Approximately 75% of melanomas have known driver oncogenic mutations in BRAF, NRAS, GNA11 or GNAQ, while the mutations providing constitutive oncogenic signaling in the remaining melanomas are not known.
Atefi, Mohammad, Avramis, Earl, Chmielowski, Bartosz, Friedman, Michael, Graeber, Thomas G, Lassen, Amanda, Le, Allison, Lomova, Anastasia, Ng, Charles, Ribas, Antoni, Titz, Bjoern, Tsoi, Jennifer   +11 more
core   +3 more sources

Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China

Diagnostic Pathology, 2019
Background To determine the relevance of the single or combination mutations of BRAF V600E, TERT, and NRAS genes and the clinicopathologic relationship in papillary thyroid cancer (PTC).
Meiling Huang, Changjiao Yan, Jingjing Xiao, Ting Wang, Rui Ling   +4 more
doaj   +1 more source

BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Carcinoma in Chinese Patients. [PDF]

PLoS ONE, 2016
BACKGROUND:The BRAF V600E and telomerase reverse transcriptase (TERT) promoter mutations have been reported in papillary thyroid carcinoma (PTC). The aim of this retrospective cross-sectional study was to add further information regarding the prevalence ...
Jian Sun, Jing Zhang, Junliang Lu, Jie Gao, Xinyu Ren, Lianghong Teng, Huanli Duan, Yansong Lin, Xiaoyi Li, Bo Zhang, Zhiyong Liang   +10 more
doaj   +1 more source

BRAF and KRAS mutations in papillary thyroid carcinoma in the United Arab Emirates.

PLoS ONE, 2020
BackgroundPapillary thyroid carcinoma (PTC) is the most common malignant thyroid neoplasm comprising 80-90% of all thyroid malignancies. Molecular changes in thyroid follicular cells are likely associated with the development of PTC.
Suhail Al-Salam, Charu Sharma, Bachar Afandi, Khaled Al Dahmani, Ali S Al-Zahrani, Amal Al Shamsi, Juma Al Kaabi   +6 more
doaj   +1 more source

BRAF V600E mutation in papillary thyroid carcinoma: it’s relation to clinical features and oncologic outcomes in a single cancer centre experience

Endocrine Connections, 2021
Purpose: This study focuses on the oncologic influence of BRAF V600E mutations in a cohort of Middle Eastern papillary thyroid carcinoma (PTC) patients treated at a single centre.
Mahmoud Al-Masri, Tawfiq Al-Shobaki, Hani Al-Najjar, Rafal Iskanderian, Enas Younis, Niveen Abdallah, Abdelghani Tbakhi, Hussam Haddad, Mohammad Al-Masri, Zeinab Obeid, Awad Jarrar   +10 more
doaj   +1 more source

A study of pathological characteristics and BRAF V600E status in Langerhans cell histiocytosis of Vietnamese children [PDF]

Journal of Pathology and Translational Medicine, 2021
Background Langerhans cell histiocytosis (LCH) is more common in children than adults and involves many organs. In children, the BRAF V600E mutation is associated with recurrent and high-risk LCH.
Thu Dang Anh Phan, Bao Gia Phung, Tu Thanh Duong, Vu Anh Hoang, Dat Quoc Ngo, Nguyen Dinh The Trinh, Tung Thanh Tran   +6 more
doaj   +1 more source

Targeting Oncogenic BRAF: Past, Present, and Future. [PDF]

, 2019
Identifying recurrent somatic genetic alterations of, and dependency on, the kinase BRAF has enabled a "precision medicine" paradigm to diagnose and treat BRAF-driven tumors.
Bivona, Trever G, Wu, Wei, Zaman, Aubhishek   +2 more
core   +1 more source

ENDOCRINE TUMORS: BRAF V600E mutations in papillary craniopharyngioma [PDF]

European Journal of Endocrinology, 2016
Papillary craniopharyngioma (PCP) is an intracranial tumor that results in high levels of morbidity. We recently demonstrated that the vast majority of these tumors harbor the oncogenic BRAF V600E mutation. The pathologic diagnosis of PCP can now be confirmed using mutation specific immunohistochemistry and targeted genetic testing.
Priscilla K, Brastianos, Sandro, Santagata   +1 more
openaire   +2 more sources